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Introduction: Infection with Epstein-Barr virus (EBV) has been suggested to contribute to the pathogenesis of
systemic lupus erythematosus (SLE). We sought to determine whether prior infection with the virus occurs more
frequently in patients with SLE compared to matched controls.
Methods: We performed a systematic review and meta-analyses of studies that reported the prevalence of anti-EBV
antibodies in the sera from cases of SLE and controls by searching Medline and Embase databases from 1966 to
2012, with no language restriction. Mantel-Haenszel odds ratios (OR) for the detection of anti-EBV antibodies were
calculated, and meta-analyses conducted. Quality assessments were performed using a modified version of the
Newcastle-Ottawa scale.
Results: Twenty-five case–control studies were included. Quality assessment found most studies reported
acceptable selection criteria but poor description of how cases and controls were recruited. There was a statistically
significant higher seroprevalence of anti-viral capsid antigen (VCA) IgG (OR 2.08; 95% confidence interval (CI) 1.15 – 3.76,
p = 0.007) but not anti-EBV-nuclear antigen1 (EBNA1) (OR 1.45; 95% CI 0.7 to 2.98, p = 0.32) in cases compared to
controls. The meta-analyses for anti-early antigen (EA) /D IgG and anti-VCA IgA also showed significantly high ORs
(4.5; 95% CI 3.00 to 11.06, p < 0.00001 and 5.05 (95% CI 1.95 – 13.13), p = 0.0009 respectively). However, funnel plot
examination suggested publication bias.
Conclusions: Overall, our findings support the hypothesis that infection with EBV predisposes to the development of
SLE. However, publication bias cannot be excluded and the methodological conduct of studies could be improved,
with regard to recruitment, matching and reporting of blinded laboratory analyses.Introduction
The pathogenesis of autoimmune diseases involves a com-
plex interplay between genetic, environmental and sto-
chastic factors. However, the precise nature and relative
importance of these remain unclear. Advancement of our
understanding of the environmental factors responsible for
autoimmunity has, on the whole, lagged that of genetic fac-
tors. Much interest has focused on the role of infection in
triggering autoimmune disorders, including systemic lupus
erythematosus (SLE), by such mechanisms as molecular* Correspondence: m.a.vickers@abdn.ac.uk
4Division of Applied Medicine, University of Aberdeen, Aberdeen AB25 2ZD, UK
5Blood Transfusion Centre, Foresterhill Road, Aberdeen AB25 2ZW, UK
Full list of author information is available at the end of the article
© 2014 Hanlon et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormimicry, bystander activation and epitope spreading [1].
Epstein–Barr virus (EBV) is one such agent that has been
implicated partly because of its lymphotropism, protean ef-
fects on the immune system and its well-documented pre-
disposing role in the development of multiple sclerosis
(MS), in which prior infection with EBV approaches 100%,
although causality remains uncertain [2-6]. However, it is
not clear whether this association is MS specific or holds
for other autoimmune conditions.
EBV has the structure common to all herpes viruses of
a large double-stranded DNA genome enclosed with an
icosahedral capsid, including viral capsid antigen (VCA).
Infection is usually not associated with symptoms when
contracted in the first decade of life. Primary infectionLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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osis. The virus infects B cells and establishes a latent cycle,
persisting for life within the long-lived memory B-cell
population of the host [7]. During latency, protein expres-
sion is limited; most commonly Epstein–Barr virus nuclear
antigen (EBNA)-1, but may include other EBNAs. Periodic
productive replication is associated with expression of
a large number of lytic cycle genes, including VCA and
early antigen (EA) [8]. EBV possesses a number of immu-
nomodulatory properties including apoptosis inhibition,
changes in cytokine secretion and the production of viral
interleukin-10 [9]. Most diagnostic tests for EBV detect
the presence of antibodies specific for EBV viral antigens.
Antibodies to VCA appear within a few weeks of infection,
are mainly IgM for the first month or two and IgG there-
after, which persist for life. Antibodies (IgG) to EBNA1
take several months to develop, but also persist for life.
IgG to EA appears in the acute phase, but falls to un-
detectable levels after a few months in 80% of individuals,
although persisting in ~20%. The presence of the anti-
bodies is said to be indicative of reactivation. IgA anti-
bodies to VCA are present in ~20% of healthy individuals,
but appear to be more prevalent in diseases where EBV
has been implicated in their aetiology, notably ~90% in pa-
tients with EBV-associated nasoopharyngeal carcinoma,
and are used both to assess patients [10] and as a screen-
ing test [11].
The nature of the association between EBV and auto-
immunity, in particular the question of causality, remains
to be fully elucidated. If the virus is an important factor, it
follows that prior infection must be more common in
those with the disease than healthy controls. Indeed, an
association between MS and the virus has been demon-
strated in several meta-analyses and infection predates de-
velopment of the disease [12]. Several mechanisms have
been postulated to explain the association, some of which
might be particular to MS, but others would be expected
to cause a more generic predisposition to autoimmunity.
Establishing whether EBV infection is linked with other
autoimmune diseases would therefore be useful in deter-
mining whether the virus is important in the development
of autoimmunity in general or whether it is implicated
only in specific immune-mediated conditions. Several
studies have claimed that SLE is associated with EBV
[13,14], but these findings have not been reported consist-
ently [15]. A difficulty in answering this question arises
from the high background seroprevalence of EBV (usually
>90% among adults), which necessitates that studies re-
cruit large samples to determine significant differences be-
tween disease and control groups. However, most studies
concerning EBV seroprevalence in SLE are of relatively
small numbers; frequently <100. A meta-analysis of such
studies is therefore likely to provide greater clarity on what
is still an unresolved question. We present the results of,to our knowledge, the first systematic review and meta-
analysis of the seropositivity rate of EBV among SLE pa-
tients compared with controls.
Methods
The systematic review was carried out according to a pre-
specified protocol developed by the authors (Additional
file 1).
Search strategy
The Medline and EMBASE databases were searched using
a combination of MeSH and Emtree headings and text
words (Additional file 1: Table S1), compiled using Ovid
search tools, for SLE and EBV. A search was conducted,
without language restriction, for articles from 1966 to
week one of November 2012.
For a study to be included in the review, it had to be a
case–control or cohort study recruiting both patients with
SLE and controls (healthy or nonhealthy). The study had to
assay serum IgG or IgA antibodies to EBV in each group.
We considered studies from any region and in any language.
Studies were considered regardless of serological assay used
and EBV antigen detected. Nonhuman studies were ex-
cluded, as were studies that only measured IgM responses.
Two authors reviewed a sample of 200 titles and abstracts
to identify those for which full texts should be sought and
those likely to be eligible for inclusion. A kappa statistic of
agreement (calculated using SPSS: IBM, New York, NY
10504, USA) was high for both outcomes (0.77 and 0.95,
respectively). Titles and abstracts of all articles were read by
one author, all potentially relevant articles were identified
and full texts of these articles were screened for eligibility.
Any uncertainties were resolved by discussion between the
authors. Reference lists of included studies were hand
searched and citation searches of all relevant articles were
conducted using the Web of Science: Thomson Reuters,
New York, NY 10036 USA citation search tool to identify
any additional articles not identified from the database
search. Relevant data from each article were extracted
independently by two authors using a standardised data ex-
traction form (Additional file 1). Any discrepancies were re-
solved by discussion between the authors.
Quality assessment
The quality assessment of included studies was based on
the Newcastle–Ottawa assessment scale [16]. We modi-
fied the exposure assessment criteria so that the subcat-
egories would be applicable to serological studies. Two
stars were awarded for blinding of blood sample ana-
lysts, one star for conducting the analysis in a clinical
laboratory (independently from investigators), one star
for specifying explicit laboratory cutoff values for sero-
positivity, and one star for reporting the presence or ab-
sence of missing data.
Hanlon et al. Arthritis Research & Therapy 2014, 16:R3 Page 3 of 11
http://arthritis-research.com/content/16/1/R3Data analysis
The Mantel–Haenzsel odds ratios (ORs) of seropositivity
to EBV were calculated for each anti-EBV antibody (anti-
VCA, anti-EBNA1 and anti-EA) using Review Manager
Version 5.1: Review Manager (RevMan) [Computer pro-
gram]. Version 5.1. Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2011. The ORs for
each antibody were combined in a meta-analysis. As we
anticipated study heterogeneity, we used a conservative
random-effects model with a 95% confidence interval (CI).
I2 was used to assess heterogeneity between studies [17].
One study analysed cases and controls in two, separ-
ate, race-matched groups [18]. For the purpose of meta-
analysis these were considered as two separate analyses.
We conducted post-hoc subgroup analysis testing of the
meta-analysis to compare the OR of VCA seropositivity in
the following categories to investigate potential sources of
heterogeneity: studies using community controls versus
those in which the source of controls was different or un-
specified; studies conducted in Far Eastern populations ver-
sus black populations versus other populations, including
where specific details on ethnicity were not available; and
studies using age-matched controls versus those that did not.
We sought to conduct similar analyses for blinding
of laboratory analyses; however, only one study in the
meta-analysis specified that this was done.
Results
Once duplicates had been removed, the search revealed
1,024 records. Screening of all titles and abstracts identi-
fied 55 studies potentially eligible for inclusion, for which
full texts were obtained. Thirty-one studies were excluded
(details in Additional file 1: Figure S1). The remaining
25 papers deemed eligible are summarised in Table 1
[13,15,18-40].
All included studies were case–control studies; no cohort
studies were identified. The median sample size was 60 for
the disease groups (range 14 to 230) and 50 for the control
groups (range 20 to 392). Most studies included cases of SLE
defined by the American College of Rheumatology criteria
(1982 or 1997 revision) [41,42]. The quality of the studies
was very variable, particularly concerning description of con-
trols and recruitment methods, as well as details of laboratory
techniques. Only three studies used a blinded laboratory ana-
lysis, and of these only one [18] was used in meta-analysis.
Of note, only one-half of the studies used age-matched con-
trols (shown in Table 2, along with other quality assessment
data). In light of the variability between the studies, as well as
the marked heterogeneity seen in their results, we conducted
post-hoc subgroup analyses as described above.
Anti-viral capsid antigen IgG
Fifteen studies included data on anti-VCA IgG seroposi-
tivity. These studies included a total of 1,278 SLE casesand 1,678 controls. Twelve of the studies showed a higher
proportion of anti-VCA-positive cases in the SLE group.
The overall percentage of SLE patients positive for this
assay was higher than for controls (95.0% and 88.7%, re-
spectively). Meta-analysis revealed an overall OR of 2.08
(95% CI 1.15 to 3.76, P = 0.02), indicating a significantly
higher seroprevalence of anti-VCA in patients with SLE
versus controls (Figure 1). The heterogeneity between the
studies was substantial with I2 = 60% (P = 0.002), indicat-
ing that the result should be interpreted cautiously. The
distribution in the funnel plot appeared asymmetrical,
raising the possibility that the effect may be due to publi-
cation bias (Additional file 1: Figure S2).
To allow comparison between studies in the meta-
analysis, all study participants were included in our ana-
lysis. The analysis by Parks and colleagues considers its
sample as two separate subgroups based on race (African
American vs. white) [18]. For the purposes of meta-
analysis, these were considered as two separate analyses.
VCA seroprevalence was higher in the African American
group than the white group in both the cases and controls,
with OR = 1.00 for both subgroups. There were, however,
more African American SLE cases and more white con-
trols, giving rise to OR = 1.72 when considered together,
which, as the authors acknowledge, appears to be an effect
of race rather than an association with SLE. If matching is
undertaken, failing to match control groups by race may
lead to misleading results.
James and colleagues’ 1997 study is one of only two
studies that specifically recruited young patient and con-
trol populations (median age 15.8 and 15.4, respectively)
[13]. The seroprevalence in the control group is much
lower than that observed in other studies (70%), which is
likely to account for the much higher OR in this study.
This finding is not repeated in the study by Tsai and col-
leagues, which may reflect a tendency towards viral ex-
posure at a younger age in Taiwan versus the USA [34].
On the basis of the use of age-matched and sex-matched
community controls, with analyses conducted in a blinded
manner, the highest quality studies were those by Parks
and colleagues [18] and Stratta and colleagues [31]. The
ORs for these studies were 1.00 (adjusting for race) and
0.67, respectively, not supporting an association between
SLE and anti-VCA seropositivity.
Anti-Epstein–Barr virus nuclear antigen-1 IgG
Eleven studies measured anti-EBNA1 IgG. A total of 705
SLE patients and 928 controls were included. There was
a higher proportion of anti-EBNA1-positive lupus cases
than controls (92.5% and 84.9%, respectively). Four
studies showed a higher anti-EBNA1 seroprevalence in
the control group, and one study found no difference.
Meta-analysis showed OR = 1.45 (95% CI 0.70 to 2.98,
P = 0.32), indicating that the difference in seropositivity
Table 1 Characteristics of included studies
Study ID Cases Controls
Age matching Location Total Source/type Sexa Ageb Total Source/type Sexa Ageb Anti-EBV
(IgG/IgA)
Test
used
Berkun and
colleagues [19]
‘Matched by age’ Colombia 120 1982 ACR criteria
for SLE
119:1 38.6 (11.9) 140 Healthy controls 130:10 39.1 (10.1) VCA, EBNA1,
EA (IgG)
IFA
Chen and
colleagues [20]
‘Age matched’ Taiwan 36 1997 ACR criteria
for SLE
32:4 30.7 (6.5) 36 Not specified 32:4 30.6 (6.2) VCA (IgG/IgA) IFA
Chen and
colleagues [21]
None Taiwan 94 1997 ACR criteria
for SLE
82:12 42.1 (9.8) 370 ‘Healthy volunteers’ 220:150 35.7 (13.9) VCA (IgG),
EBNA1 (IgG/IgA)
ELISA
Esen and
colleagues [37]
None Turkey 198 1997 ACR criteria
for SLE
180:18 38 (13)/17
to 74
65 Not specified 42:23 35 (7)/21
to 50
VCA, EBNA1,
EA (IgG)
ELISA
Evans [22] None USA 100 ‘Typical multi-system
disease’ and positive
LE cell test
Not specified 14 aged <20,
86 aged >20
34 Tuberculosis
patients
Not specified Not specified Anti-EBV IgG
(unspecified)
IFA
Gergely and
colleagues [23]
‘Identical age and
sex distribution’
Hungary 70 ‘Typical multi-system
disease’
Not specified Not specified 70 Not specified Not specified Not specified Anti-EBV IgG
(unspecified)
IFA
Huggins and
colleagues [24]
None UK 36 1997 ACR criteria
for SLE
36:0 45 (14) 25 Blood donors 25:0 47 (18) VCA, EBNA1,
EA (IgG)
IFA
James and
colleagues [13]
‘Similar by age’ USA 117 1982 ACR criteria
for SLE
Not specified 15.8 (2.15) 153 Siblings/
community
controls
Not specified 15.4 (2.51) VCA (IgG) ELISA
James and
colleagues. [25]
Matched by
age ±10 years
USA 196 1997 ACR criteria
for SLE
184:12 44.7 (12.4)/20
to 76
392 Selected from
predigrees from
lupus genetic study
368:24 45.9 (12.9)/20
to 84
VCA (IgG) ELISA
Kitagawa and
colleagues [26]
None Japan 65 1982 ACR criteria
for SLE
Not specified Not specified 66 ‘Healthy donors’ Not specified Not specified EBNA1 (IgG) IFA
Lau and
colleagues [27]
None Hong Kong 34 1982 ACR criteria
for SLE
Not specified Not specified 22 Not specified Not specified Not specified VCA, EA
(IgG/IgA)
IFA
Lu and
colleagues [28]
Age matched within
2 years
Taiwan 93 1997 ACR criteria
for SLE
95% female 35.2 (14.2) 370 ‘Healthy volunteers’ 95% female Not specified EBNA1 (IgA),
anti-EBV-DNase
(IgG)
ELISA
Marchini and
colleagues [29]
None Italy 40 ‘Patients attending
Clinical Immunology
Unit’
Not specified Not specified 20 Not specified Not specified Not specified EBNA1 (IgG) ELISA
Newkirk and
colleagues [39]
None Canada 70 1982 ACR criteria
for SLE
63:7 44.3 (2.5) 31 Not specified 19:12 46.5 (2.8) EA (IgG) ELISA
Ngou and
colleagues [30]
None France 33 1982 ACR criteria
for SLE
Not specified Not specified 50 Blood donors Not specified Not specified EBNA1 (IgG) IFA
Parks and
colleagues [18]
Age matched by
5-year subgroups
USA 230 1997 ACR criteria
for SLE
90% female Not specified 276 Community
controls
90% female Not specified VCA (IgG/IgA) ELISA
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Table 1 Characteristics of included studies (Continued)
Stevens and
colleagues [32]
None USA 34 ‘Classical clinical
picture’ and positive
LE cell test
All female Not specified 33 ‘Normal’ hospital
controls
All female Not specified Nuclear
reacting
antibody
ELISA
Stratta and
colleagues [31]
None Italy 60 1982 ACR criteria
for SLE
51:9 41/21 to 66 100 Blood donors 28:72 39 (15) VCA, EA (IgG) IFA
Sun and
colleagues [15]
‘Mean age matched
between cases and
controls’
China 108 1997 ACR criteria
for SLE
93:15 34.1 (12.1) 122 ‘Healthy controls’ 111:11 33.5 (7.6) VCA or EBNA1
(IgG)
ELISA
Tazi and
colleagues [33]
‘Age matched’ Morocco 44 1997 ACR criteria
for SLE
39:5 33/19 to 55 44 Blood donors 39:5 33/19 to 55 VCA, EBNA1
(IgG)
ELISA
Tsai and
colleagues [34]
‘Age matched’ Taiwan 16 1982 ACR criteria
for SLE
Not specified 16.9 (3.3) 20 Not specified Not specified 12.3 (2.6) VCA (IgG) IFA
Us and
colleagues [38]
None Turkey 50 1997 ACR criteria
for SLE
Not specified Not specified 50 Blood donors Not specified 35 (14) VCA, EBNA1,
EA (IgG)
ELISA
Westgeest and
colleagues [40]
None Netherlands 14 1982 ACR criteria
for SLE
Not specified Not specified 84 Blood donors Not specified Not specified EBNA1 IgG IFA
Yokochi and
colleagues [35]
None Japan 16 1982 ACR criteria
for SLE
All female 53 (12)/27
to 72
30 ‘Healthy donors’ 26:4 46 (9)/30
to 69
VCA, EBNA,
EA (IgG)
IFA
Zhang and
colleagues. [36]
None China 36 ‘SLE’ Not specified Not specified 45 ‘Normal controls’ Not specified Not specified VCA (IgG/IgA) IFA
Ethnicity: no data were available on ethnicity of cases and controls except from the analysis by Parks and colleagues, in which 60% of cases and 30% of controls were African American [18]. ACR, American College of
Rheumatology; EA, early antigen; EBNA, Epstein–Barr virus nuclear antigen; EBV, Epstein–Barr virus; ELISA, enzyme-linked immunosorbent assay; IFA, immunofluorescence assay; LE, lupus erythematosis; SLE, systemic
lupus erythematosus; VCA, viral capsid antigen. aFemale:male number and/or ratio. bMean (standard deviation) and/or range.
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Table 2 Newcastle–Ottawa assessment scale quality assessment
Study ID Selection Comparability Exposure
S1 S2 S3 S4 C1 C2 E1a E1b E2 E3 E4
Berkun and colleagues [19] * – * * * * – – – * –
Chen and colleagues [20] * – – – * * – – * * –
Chen and colleagues [21] * * – * – – – – * * –
Esen and colleagues [37] * * – * – – – – * * –
Evans [22] * – – * – * ** n/a * * –
Gergely and colleagues [23] – – – – * * – – * * –
Huggins and colleagues [24] * – – * – – – – – * –
James and colleagues [13] * – – – * * – – * * –
James and colleagues [25] * – – * * * – – * * –
Kitagawa and colleagues [26] * – – – – – – – – * –
Lau and colleagues [27] * – – – – – – – – * –
Lu and colleagues [28] * – – – * * – – * * –
Marchini and colleagues [29] – – – – – – – – – * –
Newkirk and colleagues [39] * – – * – – – – * * –
Ngou and colleagues [30] * – – – – – – – – * –
Parks and colleagues [18] * * * – * * ** n/a * * –
Stratta and colleagues [31] * – – * – * – * – * –
Stevens and colleagues [32] – – – * – – ** n/a – * –
Sun and colleagues [15] * – – * * * – – – * –
Tazi and colleagues [33] * * – * * * – – * * *
Tsai and colleagues [34] * – – * * – – – * * –
Us and colleagues [38] * – – * – – – – – * –
Westgeest and colleagues [40] * – – * – – – – – * –
Yokochi and colleagues [35] * – – * – – – – – * –
Zhang and colleagues [36] – – * * – – – * * * –
S1, objective case definition used; S2, cases consecutively recruited or obviously representative; S3, community controls; S4, controls specified as having no history
of disease; C1, controls matched for age; C2, controls matched for another factor; E1a, samples analysts blind to patient group (two stars); E1b, analysis conducted
in clinical laboratory; E2, explicit laboratory cutoff value for positive result; E3, same method of ascertainment for cases and controls; E4, missing data reported.
n/a, not available.
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was not significant (Figure 2). Heterogeneity was also
high with I2 = 60% (P = 0.007).Anti-early antigen IgG
Seven studies reported data on anti-EA seropositivity,
with a total of 568 SLE cases and 368 controls. All as-
says were of antibodies to the EA/D antigen. Rates were
significantly lower compared with anti-VCA and anti-
EBNA-1 (46% and 11% positive for anti-EA in SLE and
control groups, respectively). Meta-analysis showed a
significant association between these antibodies and
SLE, with OR = 5.76 (95% CI 3.00 to 11.06, P < 0.00001)
(Figure 3). Testing for heterogeneity showed I2 = 61%
(P = 0.02).Anti-viral capsid antigen IgA
Four studies also assayed anti-VCA antibodies of the IgA
subclass, which we undertook as a post-hoc analysis. These
studies included 372 SLE patients and 415 controls. All
showed a positive association between seropositivity and
SLE, with an overall OR of 5.05 (95% CI 1.95 to 13.13,
P = 0.0009) (Figure 4). Heterogeneity was again high with
I2 = 64% (P = 0.04). In the subgroup analysis carried out by
Parks and colleagues the OR was higher in the African
American group than the white group (5.6 (95% CI 3.0 to
10.6) and 1.6 (95% CI 0.94 to 2.7), respectively) [18].
Subgroup analyses
The results of the exploratory post-hoc subgroup ana-
lyses are shown in Additional file 1: Figures S3, S4, S5.
These were carried out to identify factors that might
Figure 1 Random effects meta-analysis of seroprevalence of anti-viral capsid antigen IgG between systemic lupus erythematosus cases
and controls. CI, confidence interval; M-H, Mantel–Haenzsel; SLE, systemic lupus erythematosus.
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trend was seen in the results for source of controls. Those
with community controls showed a lower OR than those
with other or unspecified sources (1.16 vs. 2.51), although
the difference was not significant (P = 0.12). No trends
were seen in the other subgroups.
Discussion
This meta-analysis of case–control studies investigating
the association between SLE and serological markers of
EBV infection shows a significant association between
the disease and anti-VCA IgG (OR = 2.08, 95% CI 1.15 to
3.76) but not between SLE and anti-EBNA1 IgG (1.45,
95% CI 0.70 to 2.96). We also found stronger associations
between SLE and both anti-EA/D IgG and anti-VCA IgAFigure 2 Random effects meta-analysis of seroprevalence of anti-Epst
erythematosus cases and controls. CI, confidence interval; M-H, Mantel–(OR 5.76 (95% CI 3.00 to 11.06) and 5.05 (95% CI 1.95 to
13.13), respectively). This analysis is, to our knowledge,
the first attempt to combine such estimates of association
with SLE in a meta-analysis and should therefore provide
a more robust estimate of the association than individual
studies, which have tended to include relatively small
numbers of participants. One should note, however, that
the studies included varied widely in their quality, and
there was considerable heterogeneity in the results of the
meta-analyses. Our post-hoc subgroup analyses failed to
demonstrate a significant difference between any of the
subgroups considered, although they did show a trend to-
wards higher ORs in studies lacking a community control
group. This observation, coupled with the observation
that the highest quality studies according to the qualityein–Barr virus nuclear antigen-1 IgG between systemic lupus
Haenzsel; SLE, systemic lupus erythematosus.
Figure 3 Random effects meta-analysis of seroprevalence of anti-early antigen IgG between systemic lupus erythematosus cases and
controls. CI, confidence interval; M-H, Mantel–Haenzsel; SLE, systemic lupus erythematosus.
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concern that differences in methodology and study popu-
lation may account for the heterogeneity and perhaps the
effect seen.
While a number of observations have been made link-
ing EBV to autoimmune disease generally, and SLE spe-
cifically [43,44], it remains uncertain whether there is a
causal relationship between the virus and autoimmunity.
If the relationship was causal, the prevalence of anti-
bodies against EBV antigens should be higher in patients
than controls, although a higher prevalence need not ne-
cessarily imply causality. The association between prior
infection with EBV and MS has been established beyond
reasonable doubt, with the rate of seropositivity to EBV
in MS approaching 100% [4,5,13,45]. Furthermore, infec-
tion with the virus predates disease development [12],
but causality has yet to be proven [6]. The ORs in our
analysis are lower than that seen in meta-analyses of MS
[5,45] and the overall proportion of SLE patients with
antibodies to VCA and EBNA1 was lower in our analysis
(95% and 92%, respectively). Antibodies to VCA are gen-
erally considered to be a more sensitive indicator of
prior infection with EBV. The association of SLE with
anti-EBNA1 in our analysis was not statistically signi-
ficant. In contrast, studies with MS have consistently
found reactivity to EBNA1 to be associated with theFigure 4 Random effects meta-analysis of seroprevalence of anti-vira
and controls. CI, confidence interval; M-H, Mantel–Haenzsel; SLE, systemicdisease. Overall the evidence for prior exposure to EBV
being implicated in SLE appears to be less strong than
for MS, although our results would nonetheless favour
an association. If EBV were associated with other auto-
immune diseases in addition to MS, then it would be
expected that MS is associated with those diseases. In-
deed, a recent meta-analysis reported this was the case
for autoimmune thyroid disease, inflammatory bowel
disease and psoriasis [46]. Dobson concluded that there
was no association with SLE; however, the summary
odds ratio was 2.8, higher than that found for the other
diseases, albeit with wide confidence intervals (95% CI
0.76 to 10.25). Furthermore, these associations are hard
to interpret with respect to possible causation by EBV.
Numerous genetic loci predispose to several immune-
mediated diseases and it seems likely that other environ-
mental factors are shared. The fact that infection with
EBV is so common (>95%) means that effects arising
from other shared factors are likely to drown out any
signal from any differences in the small proportion who
had not been infected with the virus.
Strengths of this study include its comprehensive search
strategy, without language restriction. Conversely, meta-
analyses such as this are susceptible to publication bias,
and there is a suggestion of this in the asymmetry of the
funnel plot of those studies included in the anti-VCAl capsid antigen IgA between systemic lupus erythematosus cases
lupus erythematosus.
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claim a significant association between the antibody and
SLE, as their sample sizes are, on the whole, too small to
detect the effect and it is only when they are combined
that a significant association is seen. Of further concern is
the high level of heterogeneity between the ORs of the in-
dividual studies, the lack of consistency in matching of
cases and controls, and the lack of reporting of recruit-
ment and laboratory methodology, as seen in the quality
assessment. We hoped to find prospective studies that
would allow analysis of the relative timing of infection and
the development of SLE, but our search revealed none.
Nevertheless, infection in the general population occurs
biphasically, generally below the age of 20, and would be
expected to precede the onset of symptoms of SLE.
Our results could perhaps be explained if there were
higher false negative rates among controls or a greater
proportion of false positive results among SLE sera. The
observation that anti-VCA has been detected in nearly
100% of some normal, healthy populations makes the
former scenario unlikely. That the assays could be more
sensitive when using SLE sera, which have been shown
to have elevated overall titres of anti-EBV antibodies as
well as hypergammaglobulinaemia in general, is a more
plausible explanation for the result being spurious, and
this cannot be ruled out.
The associations between anti-EA IgG and anti-VCA
IgA seen here are more marked than with anti-VCA or
anti-EBNA1. Unlike anti-VCA and anti-EBNA1 IgG, which
persist following exposure, antibodies to EA/D are held to
be detectable for only a transient period following primary
infection and to rise again following reinfection or reactiva-
tion of EBV, in which the virus switches from latent to lytic
cycles of replication within memory B cells. The fact that
SLE sera in our analysis had significantly higher rates of
anti-EA/D reactivity may implicate EBV reactivation in
precipitating an autoimmune reaction; conversely, it may
reflect an alteration in the relationship between the im-
mune system and the virus in the setting of SLE. A third
possibility is that immunosuppressive therapy used to treat
the disease might lead to viral reactivation and an anti-EA/
D response. Cross-linking of immunoglobulins on latently
infected memory B cells has been shown to precipitate the
lytic cycle of viral replication [43], and this is seen in other
disease states such as malaria [44]. Similar mechanisms
are possibly at work in SLE, and the anti-EA response is
possibly a serological marker of altered viral behaviour in
response to, rather than as a cause of, an altered immuno-
logical state. Esen and colleagues found that, along with
SLE patients, a higher proportion of those with systemic
sclerosis and primary anti-phospholipid syndrome had
antibodies to EA compared with controls. These groups
were not on any immunosuppressive therapy, indicating a
genuine association with the autoimmune state [37]. Oneshould note that the meta-analyses of EBV seropositivity
in MS found no association with anti-EA responses. IgA
responses to EBV have also been suggested to be asso-
ciated with viral reactivation or reinfection [47], which
would support an association between this state and SLE.
The study with highest OR for anti-VCA IgG was by
James and colleagues [13]. This was one of only two paedi-
atric studies. The other paediatric study found a weaker
association, although the sample size was much smaller,
with only 16 cases with SLE and 20 controls [34]. The
high OR of the former study could be in part due to the
lower seroprevalence of EBV in a paediatric control popu-
lation, or could reflect a role for EBV in SLE close to time
of onset, or in paediatric cases specifically. A further study
also supports the importance of EBV in paediatric SLE, in
which 36 patients and controls, all of whom had IgG
to VCA, were tested for anti-EBNA1 IgG. All 36 patients
with SLE and only 25 of the controls had antibodies to the
antigen. Epitope mapping suggested that the response of
the SLE group was distinct in its specificity from the
normal control group. No significant differences were de-
tected in responses to other herpes viruses. The strength
of the association in children, as well as the lower back-
ground EBV seroprevalence in younger groups, highlights
the importance of age matching of control groups when
conducting case–control studies in this area. Parks and
colleagues observed that the association of anti-VCA IgA
with SLE in their white subgroup became stronger with
increasing age [18], indicating that age matching may be
important among adult as well as paediatric populations.
It is therefore of concern that just over one-half of the
studies included in this analysis matched for age according
to the authors.Conclusion
In summary, these findings support the hypothesis that
prior infection with EBV is important in the develop-
ment of SLE, as indicated by a higher seroprevalence
of anti-VCA IgG. The results also suggest dysregulated
(anti-EA/D, IgA) immune responses to EBV in the con-
text of SLE. The studies included in this meta-analysis,
however, are heterogeneous and, on the whole, have small
sample sizes. Many do not match for age and sex, few
match for race, and a specific description of recruitment
and laboratory practice is lacking in many of the re-
ports. The role of publication bias cannot be excluded.
Further, larger studies with more precise matching and
descriptions of recruitment and measurement, ideally
using prospective serological measurements, addressing
the questions of both precedence and the possibility of
spurious results from abnormal humoral immune re-
activity secondary to the disease, are needed to establish
the relationship between infection with EBV and SLE.
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